-
7-{[(3aR,6aS)-2-methyl-octahydrocyclopenta[c]pyrrol-5-yl]methoxy}-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
-
ChemBase ID:
73299
-
Molecular Formular:
C24H25Cl2FN4O2
-
Molecular Mass:
491.3853032
-
Monoisotopic Mass:
490.13385964
-
SMILES and InChIs
SMILES:
n1cnc2c(c1Nc1ccc(c(c1F)Cl)Cl)cc(c(c2)OCC1C[C@@H]2[C@H](C1)CN(C2)C)OC
Canonical SMILES:
COc1cc2c(cc1OCC1C[C@@H]3[C@H](C1)CN(C3)C)ncnc2Nc1ccc(c(c1F)Cl)Cl
InChI:
InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
InChIKey:
HVXKQKFEHMGHSL-GOOCMWNKSA-N
-
Cite this record
CBID:73299 http://www.chembase.cn/molecule-73299.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
7-{[(3aR,6aS)-2-methyl-octahydrocyclopenta[c]pyrrol-5-yl]methoxy}-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
|
|
|
IUPAC Traditional name
|
7-{[(3aR,6aS)-2-methyl-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy}-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
|
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
13.4573345
|
H Acceptors
|
6
|
H Donor
|
1
|
LogD (pH = 5.5)
|
1.7662418
|
LogD (pH = 7.4)
|
2.8389034
|
Log P
|
5.2485213
|
Molar Refractivity
|
127.7627 cm3
|
Polarizability
|
50.080173 Å3
|
Polar Surface Area
|
59.51 Å2
|
Rotatable Bonds
|
6
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Selleck Chemicals
Selleck Chemicals -
S1083
|
Biological Activity: The activity of EXEL-7647 (XL647), a novel spectrum-selective kinase inhibitor with potent activity against the EGF and vascular endothelial growth factor receptor tyrosine kinase families, against both wild-type (WT) and mutant EGFR in vitro and in vivo[1,2] .EXEL-7647 potently inhibits the EGFR and ErbB2 with IC50 0.3 and 16 nM respectively[2] .EXEL-7647 inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors a double mutation (L858R and T790M) in the EGFR gene. EXEL-7647 substantially inhibited the growth of H1975 xenograft tumors and reduced both tumor EGFR signaling and tumor vessel density. Additionally, EXEL-7647 substantially inhibited the growth and vascularization of MDAMB-231 xenografts, a model which is more reliant on signaling through vascular endothelial growth factor receptors[2] .References on XL647[1] Clin Cancer Res., 2008 Apr 15, 14(8):2465-75.[2] Clin Cancer Res., 2007 Jun 15, 13(12):3713-23 |
PATENTS
PATENTS
PubChem Patent
Google Patent